发明授权
US07727518B2 Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
有权
使用IL-29半胱氨酸突变体治疗丙型肝炎和乙型肝炎的方法
- 专利标题： Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
- 专利标题（中）： 使用IL-29半胱氨酸突变体治疗丙型肝炎和乙型肝炎的方法
-
申请号： US12043885申请日： 2008-03-06
-
公开(公告)号： US07727518B2公开(公告)日： 2010-06-01
- 发明人: Lowell J. Brady , Kevin M. Klucher , Chung Chan , Dennis L. Dong , Hong Y. Liu , Paul O. Sheppard , Thomas R. Bukowski
- 申请人： Lowell J. Brady , Kevin M. Klucher , Chung Chan , Dennis L. Dong , Hong Y. Liu , Paul O. Sheppard , Thomas R. Bukowski
- 申请人地址： US TN Nashville
- 专利权人： ZymoGenetics, LLC
- 当前专利权人： ZymoGenetics, LLC
- 当前专利权人地址： US TN Nashville
- 代理商 Brian J. Walsh
- 主分类号： A61K38/19
- IPC分类号： A61K38/19 ; A61K45/00
摘要：
Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
公开/授权文献
- US20080279816A1 HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29 公开/授权日：2008-11-13